Obesity and diabetes

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 13, Issue 2, 1999, Pages 221-237

  Leong, King Sun ^a   Wilding, John P ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Leptin; Non esterified fatty acids; Obesity; Orlistat; Sibutramine; Tumour necrosis factor ; Type 2 diabetes; Uncoupling proteins

Indexed keywords

ANTIOBESITY AGENT; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; PHOSPHATASE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN;

BEHAVIOR; BLOOD GLUCOSE MONITORING; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIET; EXERCISE; FLATULENCE; HORMONE BLOOD LEVEL; HUMAN; INSOMNIA; INSULIN RESISTANCE; LEPTIN BLOOD LEVEL; MALABSORPTION; OBESITY; PANCREAS ISLET BETA CELL; PATIENT EDUCATION; PREVALENCE; REVIEW; SYMPATHETIC TONE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0033508761     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.1999.0017     Document Type: Article

References (111)

1. Morris R D, Rimm D L, Hartz A J. Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32,662 adult white women. American Journal of Epidemiology. 130:1989;112-121.
2. Skarfors E T, Selinus K I, Lithell H O. Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. British Medical Journal. 303:1991;755-760.
3. Haffner S M, Stern M P, Mitchell B D. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes. 39:1990;283-288.
4. Charles M A, Fontbonne A, Thibult N. Risk factors for NIDDM in white population. Paris prospective study. Diabetes. 40:1991;796-799.
5. World Health Organization, Prevention of diabetes mellitus, Geneva, WHO, 1997.
6. Mathus-Vliegen E MH. Overweight. I: Prevalences and trends. Nederlands Tijdschrift voor Geneeskunde. 142:1998;1982-1989.
7. Dobson A J, Evans A, Ferrario M. Changes in estimated coronary risk in the 1980s: data from 38 populations in the WHO MONICA Project. Annals of Medicine. 30:1998;199-205.
8. Acting on Australia's Weight: A Strategic Plan for the Prevention of Overweight and Obesity. 1997;Australian Government Publishing Service, Canberra. p. 85-95.
9. Levy E, Levy P, Le Pen C, Basdevant A. The economic cost of obesity: the French situation. International Journal of Obesity. 19:1995;788-792.
10. Seidell J C. Obesity in Europe - causes, costs, and consequences. International Journal of Risk and Safety in Medicine. 7:1995;103-110.
11. Wolf A M, Colditz G A. The costs of obesity. American Journal of Clinical Nutrition. 55:1992;503S-507S.
12. Larsson B, Svardsudd K, Welin L. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. British Medical Journal. 288:1984;1401-1404.
13. Chan J M, Rimm E B, Colditz G A. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 17:1994;961-969.
14. Report of a WHO Consultation on Obesity. Obesity: Preventing and Managing the Global Epidemic. 1997;WHO, Geneva. p. 7-16.
15. Thomas P R. Nature and Problem of Obesity. 1995;10-11 National Academy Press, Washington.
16. Han T S, Van Leer E M, Seidell J C, Lean M EJ. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. British Medical Journal. 311:1995;1401-1405.
17. Kahn S E, Porte D Jr. Pathophysiology of type II (non-insulin dependent) diabetes mellitus: implications for treatment. Porte D Jr, Sherwin R S. Diabetes mellitus; theory and practice. 1996;487-512 Appleton and Lange, New York.
18. Kruszynska Y T. Normal metabolism: the physiology of fuel homeostasis. Pickup J, Williams G. Textbook of Diabetes. 1997;Blackwell Science, Oxford.
19. Bonadonna R C, Croop L C, Zych K. Dose-dependent effect of insulin of plasma free fatty acid turnover oxidation in humans. American Journal of Physiology. 259:1990;E736-E750.
20. Randle P J, Garland P B, Hales C N, Newholme C A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1:1963;785-789.
21. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 46:1997;3-10.
22. Macdonald I A. Advances in our understanding of the role of the sympathetic nervous system. International Journal of Obesity. 19:1995;S2-S7.
23. Spraul M, Ravussin E, Fontvieille A M. Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain. Journal of Clinical Investigation. 92:1993;1730-1735.
24. Grassi G, Cattaneo B M, Seravalle G. Obesity and the sympathetic nervous system. Blood Pressure. 5:1996;43-46.
25. Kageyama T, Nishikido N, Honda Y. Effects of obesity, current smoking status, and alcohol consumption on heart rate variability in male white-collar workers. International Archives of Occupational and Environmental Health. 69:1997;447-454.
26. Peiris A N, Struve M F, Mueller R A. Glucose metabolism in obesity: influence of body fat distribution. Journal of Clinical Endocrinology and Metabolism. 67:1988;760-767.
27. Anderson E A, Balon T W, Hoffman R P. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension. 19:1992;621-627.
28. Fagius J, Berne C. Increase in muscle nerve sympathetic activity in humans after food intake. Clinical Science. 86:1994;159-167.
29. Lillioja S, Nyomba B L, Saad M F. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. Journal of Clinical Endocrinology and Metabolism. 73:1991;866-876.
30. DeFronzo R A. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia. 35:1992;389-397.
31. O'Rahilly S P, Nugent Z, Rudenski A S. Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet. 2:1986;360-364.
32. Hales C N, Barker D J. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 35:1992;595-601.
33. Yki-Jarvinen H. Glucose toxicity. Endocrine Reviews. 13:1992;415-431.
34. Scherbaum W A. The role of amylin in the physiology of glycemic control. Experimental and Clinical Endocrinology and Diabetes. 106:1998;97-102.
35. Zhang Y, Proenca R, Maffei M. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:1994;425-432.
36. Flier J S. Leptin expression and action: new experimental paradigms. Proceedings of the National Academy of Sciences of the US. 94:1997;4242-4245.
37. Schwartz M W, Seeley R J. Neuroendocrine responses to starvation and weight loss. New England Journal of Medicine. 336:1997;1803-1811.
38. Maffei M, Halaas J, Ravussin E. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Medicine. 1:1995;1155-1161.
39. Considine R V, Sinha M K, Heiman M L. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine. 334:1996;292-295.
40. Segal K R, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes. 45:1996;988-991.
41. Mantzoros C S, Moschos S, Avramopoulos I. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. Journal of Clinical Endocrinology and Metabolism. 82:1997;3408-3413.
42. Emilsson V, Liu Y L, Cawthorne M A. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes. 46:1997;313-316.
43. Koyama K, Chen G, Wang M Y. Beta cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy. Diabetes. 48:1997;1276-1280.
44. Ookuma M, Ookuma K, York D A. Effects of leptin on insulin secretion from isolated rat pancreatic islets. Diabetes. 47:1998;219-223.
45. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science. 274:1996;1185-1188.
46. Wang Y, Kuropatwinski K K, White D W. Leptin receptor action in hepatic cells. Journal of Biological Chemistry. 272:1997;16216-16223.
47. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. Journal of Biological Chemistry. 272:1997;10585-10593.
48. Walder K, Filippis A, Clark S. Leptin inhibits insulin binding in isolated rat adipocytes. Journal of Endocrinology. 155:1997;R5-R7.
49. Furnsinn C, Brunmair B, Furtmuller R. Failure of leptin to affect basal and insulin-stimulated glucose metabolism of rat skeletal muscle in vitro. Diabetologia. 41:1998;524-529.
50. Ranganathan S, Ciaraldi T P, Henry R R. Lack of effect of leptin on glucose transport, lipoprotein lipase, and insulin action in adipose and muscle cells. Endocrinology. 139:1998;2509-2513.
51. Haynes W G, Sivitz W I, Morgan D A. Sympathetic and cardiorenal actions of leptin. Hypertension. 30:1997;619-623.
52. Snitker S, Pratley R E, Nicolson M. Relationship between muscle sympathetic nerve activity and plasma leptin concentration. Obesity Research. 5:1997;338-340.
53. Ricquier D, Bouillaud F. The mitochondrial uncoupling proteins. Médécine/Sciences. 14:1998;889-897.
54. Stock M. Energy balance and animal models of obesity. Kopelman P G, Stock M. Clinical Obesity. 1998;50-72 Blackwell Science, Oxford.
55. Emilsson V, Summers R J, Hamilton S. The effects of the beta3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression. Biochemical and Biophysical Research Communications. 252:1998;450-454.
56. Savontaus E, Rouru J, Boss O. Differential regulation of uncoupling proteins by chronic treatments with beta3-adrenergic agonist BRL 35135 and metformin in obese fa/fa zucker rats. Biochemical and Biophysical Research Communications. 246:1998;899-904.
57. Matsuda J, Hosoda K, Itoh H. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes. Diabetes. 47:1998;1809-1814.
58. Walder K, Norman R A, Hanson R L. Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima Indians. Human Molecular Genetics. 7:1998;1431-1435.
59. White M F. The IRS-signalling system: a network of docking proteins that mediate insulin action. Molecular and Cellular Biochemistry. 182:1998;3-11.
60. Hotamisligil G S, Shargill N S, Spiegelman B M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
61. Hotamisligil G S, Arner P, Caro J F. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. Journal of Clinical Investigation. 95:1995;2409-2415.
62. Saghizadeh M, Ong J M, Garvey W T. The expression of TNF alpha by human muscle. Relationship to insulin resistance. Journal of Clinical Investigation. 97:1996;1111-1116.
63. Hotamisligil G S, Budavari A, Murray D, Spiegelman B M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. Journal of Clinical Investigation. 94:1994;1543-1549.
64. Nolte L A, Hansen P A, Chen M M. Short-term exposure to tumor necrosis factor-alpha does not affect insulin-stimulated glucose uptake in skeletal muscle. Diabetes. 47:1998;721-726.
65. Stephens J M, Pekala P H. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Journal of Biological Chemistry. 266:1991;21839-21845.
66. Stephens J M, Lee J, Pilch P F. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. Journal of Biological Chemistry. 272:1997;971-976.
67. Elchebly M, Payette P, Michaliszyn E. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1β gene. Science. 283:1999;1544-1548.
68. Lee J H, Reed D R, Price R A. Familial risk ratios for extreme obesity: implications for mapping human obesity genes. International Journal of Obesity. 21:1997;935-940.
69. Sorensen T I. The genetics of obesity. Metabolism: Clinical and Experimental. 44:1995;4-6.
70. Bouchard C. Genetics of human obesity: recent results from linkage studies. Journal of Nutrition. 127:1997;1887S-1890S.
71. Perusse L, Chagnon Y C. Summary of human linkage and association studies. Behavior Genetics. 27:1997;359-372.
72. Froguel P. Tracking down genes to cure diabetes: an achievable task for the 21st century? Diabetes and Metabolism. 23:1997;8-13.
73. Kahn C R, Vicent D, Doria A. Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annual Review of Medicine. 47:1996;509-531.
74. Velho G, Froguel P. Genetic determinants of non-insulin-dependent diabetes mellitus: strategies and recent results. Diabetes and Metabolism. 23:1997;7-17.
75. Hales C N, Barker D J, Clark P M. Fetal and infant growth and impaired glucose tolerance at age 64. British Medical Journal. 303:1991;1019-1022.
76. Phillips D I, Barker D J, Hales C N. Thinness at birth and insulin resistance in adult life. Diabetologia. 37:1994;150-154.
77. Phillips D I, Hirst S, Clark P M. Fetal growth and insulin secretion in adult life. Diabetologia. 37:1994;592-596.
78. Neel J V. Diabetes mellitus: a thrifty genotype rendered detrimental by 'progress'. American Journal of Human Genetics. 14:1962;353-362.
79. Knowler W C, Pettitt D J, Bennett P H, Williams R C. Diabetes mellitus in the Pima Indians: genetic and evolutionary considerations. American Journal of Physical Anthropology. 62:1983;107-114.
80. Lean M E, Powrie J K, Anderson A S, Garthwaite P H. Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Medicine. 7:1990;228-233.
81. World Health Statistics Quarterly. 41:1988;115-140.
82. Garner D M, Wooley S C. Confronting the failure of behavioral and dietary treatments for obesity. Clinical Psychology Review. 11:1991;729-780.
83. Wing R R, Koeske R, Epstein L H. Long-term effects of modest weight loss in type II diabetic patients. Archives of Internal Medicine. 147:1987;1749-1753.
84. Dattilo A M, Kris-Etherton P M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. American Journal of Clinical Nutrition. 56:1992;320-328.
85. Goldstein D J. Beneficial health effects of modest weight loss. International Journal of Obesity and Related Metabolic Disorders. 16:1992;397-415.
86. Karason K, Wallentin I, Larrson B, Sjostrom L. Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study. British Medical Journal. 315:1997;912-916.
87. Saris S. Effects of energy restriction and exercise on the sympathetic nervous system. International Journal of Obesity. 19:1995;S17-S23.
88. Grassi G, Seravalle G, Compton M M. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation. 97:1998;2037-2042.
89. Pories W J, Swanson M S, MacDonald K G. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Annals of Surgery. 222:1995;339-350.
90. Sjostrom L, Narbro K, Sjostrom D. Costs and benefits when treating obesity. International Journal of Obesity. 19:1995;S9-S12.
91. Kolanowski J. Surgical treatment for morbid obesity. British Medical Bulletin. 53:1997;433-444.
92. Krotkiewski M, Lonroth P, Mandroukas K. The effects of physical training in insulin secretion and effectiveness on glucose metabolism in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 28:1985;881-890.
93. Klem M L, Wing R R, McGuire M T. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. American Journal of Clinical Nutrition. 66:1997;239-246.
94. Hillsdon M, Thorogood M. A systematic review of physical activity promotion strategies. British Journal of Sports Medicine. 30:1996;84-89.
95. Frost G, Masters K, King C. A new method of energy prescription to improve weight loss. Journal of Human Nutrition and Dietetics. 4:1991;369-373.
96. Ha T, Lean M E. Diet and lifestyle modification in the management of non-insulin dependent diabetes mellitus. Pickup J, Williams G. Textbook of Diabetes. 1997;37.1-37.18 Blackwell Science, Oxford.
97. Skender M L, Goodrick G K, Del Junco D J. Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions. Journal of the American Dietetic Association. 96:1996;342-346.
98. Journal of the American Medical Association. 270:1993;967-974.
99. Uusitupa M I, Laakso M, Sarlaund H. Effects of a very low calorie diet on metabolic control and cardiovascular risk factors in the treatment of obese non-insulin dependent diabetics. American Journal of Clinical Nutrition. 51:1990;768-773.
100. Guerciolini R. Mode of action of orlistat. International Journal of Obesity and Related Metabolic Disorders. 21:1997;S12-S23.
101. Hollander P A, Elbein S C, Hirsch I B. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care. 21:1998;1288-1294.
102. Sjostrom L, Rissanen A, Andersen T. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 352:1998;167-172.
103. Melia A T, Koss-Twardy S G, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. Journal of Clinical Pharmacology. 36:1996;647-653.
104. Ryan D H, Kaiser P, Bray G A. Sibutramine: a novel new agent for obesity treatment. Obesity Research. 3:1995;553S-559S.
105. Heal D J, Aspley S, Prow M R. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. International Journal of Obesity. 22:1998;S18-S29.
106. Luque C A, Rey J A, Fernandez A. Focus on sibutramine: a new anorectic agent for the treatment of obesity. Hospital Formulary. 32:1997;1025-1039.
107. Bray G A, Ryan D H, Gordon D. A double-blind randomized placebo-controlled trial of sibutramine. Obesity Research. 4:1996;263-270.
108. Griffiths J, Byrnes A E, Frost G. Sibutramine in the treatment of overweight non-insulin dependent diabetics. International Journal of Obesity. 19:1995;144.
109. Lean M E. Sibutramine - a review of clinical efficacy. International Journal of Obesity and Related Metabolic Disorders. 21:1997;S30-S36.
110. Lancet. 352:1998;837-853.
111. Lancet. 352:1998;854-865.